A less toxic, dose-adjusted regimen of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) was effective in treating adults with Burkitt lymphoma, investigators have found.
Specifically, with median follow-up of 58.7 months, adults treated with the DA-EPOCH-R regimen had an event-free survival rate of 84.5% and overall survival of 87%. Furthermore, event-free survival was 100% and 82.1% in low- and high-risk patients, respectively.
The results, published in the Journal of Clinical Oncology, confirm results from an earlier pilot study of 30 patients.
